Veru announces preclinical results from expanded sabizabulin program into influenza-induced severe acute respiratory distress syndrome and provides update on covid-19 program

In the final report, sabizabulin significantly reduced key cytokines involved in acute respiratory distress syndrome (ards) in h1n1 influenza pulmonary inflammation murine ards model
VERU Ratings Summary
VERU Quant Ranking